Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.South Korea-based SK bioscience has entered into a development and supply agreement for Novavax Covid-19 vaccine candidate, NVX-CoV2373.
The company intends to supply the vaccine to global markets, including COVAX Facility. SK bioscience and Novavax also signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to facilitate equitable access to the vaccine worldwide, as well as in South Korea.
Under the agreement, SK bioscience will produce the vaccine antigen component for use in the final drug product across the world during the Covid-19 pandemic.